Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03846206
Other study ID # Clinic Hospital of Barcelona
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 1, 2016
Est. completion date December 1, 2019

Study information

Verified date August 2019
Source Hospital Clinic of Barcelona
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate if a change to a Mediterranean diet supplemented with nuts and olive oil decreases bacterial translocation and immune activation by a change in the microbiome in successfully treated HIV-1 infected patients with CD4> 500cells/ml.


Description:

Mediterranean diet supplemented by nuts and extra virgin olive oil has shown to reduce mortality, cardiovascular diseases, and breast cancer in HIV uninfected individuals. It is likely that changes in the microbiome could play a role in this effect. The goal of the study is to evaluate if a change to a Mediterranean diet supplemented with nuts and olive oil decreases bacterial translocation and immune activation by a change in the microbiome in successfully treated HIV-1 infected patients with CD4> 500cells/ml. One hundred and two patients who will be randomized to continues usual diet or to a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months. Throughout the study a specialized dietician will monitor the patients. Blood samples will be collected to assess parameters of bacterial translocation, inflammation and immune activation. To assess compliances with diet, urine samples will be collected too, and stool samples to study changes in gut microbiota. All the samples will be collected at the beginning and 90 days after the inclusion in the study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 102
Est. completion date December 1, 2019
Est. primary completion date September 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient = 18 years of age;

- To sign voluntary informed consent;

- Male or female patients with a negative pregnancy test before inclusion in the study;

- Proven HIV infection (with HIV-1 positive antibodies);

- Patient should be on stable treatment with cART for at least 1 year

- The mean of all CD4 measurements during the year prior to the initiation of cART should be equal to greater than 350 cells / mm3

- The number of CD4 + at the time of recruitment must be equal to or greater than 500 cells / mm3;

- HIV viral load should be undetectable at least 6 months prior to study inclusion, and less determinations (occasional blips above the undetectable level are allowed).

Exclusion Criteria:

- Acquired Immunodeficiency Syndrome.

- Active opportunistic diseases.

- Patients coinfected with HCV or HBV

- Coagulopathy

- Renal insufficiency (creatinine> 1.5 mg / dL)

- Pregnancy or breastfeeding

- Inability to sign informed consent

- Active opportunistic infections, or any active infection or cancer within 30 days prior to the screening visit;

- Therapy with immunomodulatory agents, including cytokines (eg IL-2) and gammaglobulins or chemotherapy within 90 days prior to the screening visit;

- Use of anticoagulant medication;

- Use of any type of experimental medication during the 90 days prior to study entry;

- Uncontrolled psychiatric disorder;

- Patients with uncontrolled active autoimmune diseases;

- Usual use of antibiotics

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
mediterranean diet
a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months

Locations

Country Name City State
Spain Felipen Garcia Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Hospital Clinic of Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in levels of sCD14 at baseline and month 3 between groups parameters of bacterial translocation 2 year
Secondary Changes in EndocAB and LBP levels at baseline and month 3 between groups. other parameters of bacterial translocation. 2 year
Secondary Changes in microbiota (fecal 16s rRNA) at baseline and month 3 between groups Microbioma 2 years
Secondary Changes in ultrasensitive PCR, TNF-alpha, IL-6 and Dimer-D at baseline and month 3 between groups inflammatory markers 2 years
Secondary Changes in lipids at baseline and month 3 between groups Lipids 2 years
Secondary Changes in expression of CD38, HLA DR in CD4 and CD8 T cells at baseline and month 3 between groups immune-activation markers 2 years
Secondary Changes in total and integrated DNA Marker of HIV reservoir 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2